Clear All
796 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J8610 Methotrexate Trexall 2.5 mg Chemotherapy Antimetabolite Folic Acid Analog Yes 1953 Jan 1, 1995 In Use
J9393 Fulvestrant (Teva) Fulvestrant (Teva) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
NA Carmustine wafer Gliadel 7.7mg Chemotherapy Alkylating Agent Nitrosourea No 2012 In Use
J9025 Azacitidine Vidaza 1 mg Chemotherapy Antimetabolite Pyrimidine Analog No 2004 Jan 1, 2006 In Use
NA Estrogens, Conjugated Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) multiple Hormonal Therapy Estrogen Yes 1998 In Use
NA Cervarix Human papillomavirus vaccine 20 mcg vaccine Ancillary Therapy Protective Agent HPV Vaccine No 2009 2016 In Use
J9041 Bortezomib Velcade 0.1 mg Chemotherapy Proteasome Inhibitor 26S No 2003 Jan 1, 2005 In Use
J9601 Linvoseltamab-gcpt Lynozyfic 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2025 Mar 18, 2026 In Use
NA Diethylstilbestrol DES, Stilbestrol unspecified Hormonal Therapy Estrogen No 1905 2000 In Use
NA Dinutuximab Unituxin 3.5 mg/mL Immunotherapy Monoclonal Antibody GD-2 No 2015 In Use
NA Enasidenib mesylate Idhifa 50 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
J9030 Bacillus calmette-guerin BCG Vaccine, Tice BCG 1mg Immunotherapy Biological Response Modifier Live Vaccine No 1990 Jul 1, 2019 In Use
NA Crizotinib Xalkori 200 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
J9100 Cytarabine Cytarabine 100 mg Chemotherapy Antimetabolite Pyrimidine Analog No 1998 Jan 1, 1986 In Use
J9050 Carmustine Bicnu 100 mg Chemotherapy Alkylating Agent Nitrosourea No 1977 Jan 1, 1984 In Use
NA Elacestrant Orserdu Multiple Hormonal Therapy Estrogen Receptor Antagonist ERɑ Yes 2023 In Use
J1260 Dolasetron Mesylate Anzemet 10 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1997 Jan 1, 2000 In Use
NA Afatinib Gliotrif 20 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
J9228 Ipilimumab Yervoy 1mg Immunotherapy Checkpoint Inhibitor CTLA-4 No 2011 Jan 1, 2012 In Use
J9061 Amivantamab Rybrevant 2mg Immunotherapy Monoclonal Antibody EGFR, MET No 2021 Jan 26, 2022 In Use
S0174 Dolasetron Mesylate Anzemet 50 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1997 Jan 1, 2002 In Use
J9311 Rituximab and Hyaluronidase Rituxan Hycela 10mg Immunotherapy Monoclonal Antibody CD20 No 2017 Jan 1, 2019 In Use
NA Erlotinib Tarceva 100 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
Fruquintinib Fruzaqla 1mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2023 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.